Improving translatability of preclinical studies for neuromuscular disorders : lessons from the TREAT-NMD Advisory Committee for Therapeutics (TACT)
© 2020. Published by The Company of Biologists Ltd..
Clinical trials for rare neuromuscular diseases imply, among other investments, a high emotional burden for the whole disease community. Translation of data from preclinical studies to justify any clinical trial must be carefully pondered in order to minimize the risk of clinical trial withdrawal or failure. A rigorous distinction between proof-of-concept and preclinical efficacy studies using animal models is key to support the rationale of a clinical trial involving patients. This Review evaluates the experience accumulated by the TREAT-NMD Advisory Committee for Therapeutics, which provides detailed constructive feedback on clinical proposals for neuromuscular diseases submitted by researchers in both academia and industry, and emphasizes that a timely critical review of preclinical efficacy data from animal models, including biomarkers for specific diseases, combined with adherence to existing guidelines and standard protocols, can significantly help to de-risk clinical programs and prevent disappointments and costly engagement.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Disease models & mechanisms - 13(2020), 2 vom: 07. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Willmann, Raffaella [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Animal models |
|---|
| Anmerkungen: |
Date Completed 28.01.2021 Date Revised 04.12.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1242/dmm.042903 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM306606445 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM306606445 | ||
| 003 | DE-627 | ||
| 005 | 20231225123733.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1242/dmm.042903 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1021.xml |
| 035 | |a (DE-627)NLM306606445 | ||
| 035 | |a (NLM)32066568 | ||
| 035 | |a (PII)dmm042903 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Willmann, Raffaella |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Improving translatability of preclinical studies for neuromuscular disorders |b lessons from the TREAT-NMD Advisory Committee for Therapeutics (TACT) |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.01.2021 | ||
| 500 | |a Date Revised 04.12.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020. Published by The Company of Biologists Ltd. | ||
| 520 | |a Clinical trials for rare neuromuscular diseases imply, among other investments, a high emotional burden for the whole disease community. Translation of data from preclinical studies to justify any clinical trial must be carefully pondered in order to minimize the risk of clinical trial withdrawal or failure. A rigorous distinction between proof-of-concept and preclinical efficacy studies using animal models is key to support the rationale of a clinical trial involving patients. This Review evaluates the experience accumulated by the TREAT-NMD Advisory Committee for Therapeutics, which provides detailed constructive feedback on clinical proposals for neuromuscular diseases submitted by researchers in both academia and industry, and emphasizes that a timely critical review of preclinical efficacy data from animal models, including biomarkers for specific diseases, combined with adherence to existing guidelines and standard protocols, can significantly help to de-risk clinical programs and prevent disappointments and costly engagement | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Animal models | |
| 650 | 4 | |a Clinical trial | |
| 650 | 4 | |a Efficacy studies | |
| 650 | 4 | |a Guidelines | |
| 650 | 4 | |a Neuromuscular | |
| 650 | 4 | |a Preclinical | |
| 650 | 4 | |a Standard protocols | |
| 700 | 1 | |a Lee, Joanne |e verfasserin |4 aut | |
| 700 | 1 | |a Turner, Cathy |e verfasserin |4 aut | |
| 700 | 1 | |a Nagaraju, Kanneboyina |e verfasserin |4 aut | |
| 700 | 1 | |a Aartsma-Rus, Annemieke |e verfasserin |4 aut | |
| 700 | 1 | |a Wells, Dominic J |e verfasserin |4 aut | |
| 700 | 1 | |a Wagner, Kathryn R |e verfasserin |4 aut | |
| 700 | 1 | |a Csimma, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Straub, Volker |e verfasserin |4 aut | |
| 700 | 1 | |a Grounds, Miranda D |e verfasserin |4 aut | |
| 700 | 1 | |a De Luca, Annamaria |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Disease models & mechanisms |d 2008 |g 13(2020), 2 vom: 07. Feb. |w (DE-627)NLM184855462 |x 1754-8411 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2020 |g number:2 |g day:07 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1242/dmm.042903 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2020 |e 2 |b 07 |c 02 | ||